![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2017
Anzahl der Publikationen: 2
2017
Camidge, D. Ross; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen; Hansen, Karin; Kim, Sang-We; Huber, Rudolf; West, Howard; Grön, Harry; Hochmair, Maximilian; Leighl, Natasha; Gettinger, Scott; Langer, Corey; Paz-Ares, Luis; Smit, Egbert; Kim, Edward; Reichmann, William; Clackson, Tim; Kerstein, David; Haluska, Frank und Kim, Dong-Wan
(2017):
Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S1167-S1169
Gettinger, Scott; Kim, Dong-Wan; Tiseo, Marcello; Langer, Corey; Ahn, Myung-Ju; Shaw, Alice; Huber, Rudolf; Hochmair, Maximilian; Kim, Sang-We; Bazhenova, Lyudmila; Gold, Kathryn; Ou, Sai-Hong; West, Howard; Reichmann, William; Haney, Jeff; Clackson, Tim; Haluska, Frank; Kerstein, David und Camidge, D. Ross
(2017):
Brigatinib Activity in Patients with ALK plus NSCLC and Intracranial CNS Metastases in Two Clinical Trials.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S273-S274